Download or read book Angiogenesis Therapeutic Targets in Cancer written by Malay Chatterjee and published by Bentham Science Publishers. This book was released on 2010 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis plays rate limiting roles in tumor growth and invasion. Angiogenesis inhibition has been proposed as a general strategy to fight against cancers. This book covers different therapeutic targets for angiogenesis interventions with emphasis on c
Download or read book Angiogenesis and therapeutic targets in cancer written by Malay Chatterjee and published by . This book was released on 2010 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis plays rate limiting roles in tumor growth and invasion. Angiogenesis inhibition has been proposed as a general strategy to fight against cancers. This book covers different therapeutic targets for angiogenesis interventions with emphasis on c
Download or read book Tumor Angiogenesis written by Dieter Marmé and published by Springer Science & Business Media. This book was released on 2007-12-05 with total page 840 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
Download or read book Tumor Angiogenesis written by Francis S. Markland and published by John Wiley & Sons. This book was released on 2010-06-08 with total page 353 pages. Available in PDF, EPUB and Kindle. Book excerpt: Themen dieses Bandes sind die molekularen Mechanismen der Tumor-Angiogenese, die Suche nach einschlägigen Targets für die Wirkstoffforschung und die Entwicklung von Kombinationstherapien mit bereits existierenden Ansätzen. Die ideale Informationsquelle für Studenten, Ärzte und Forscher in der Pharmaindustrie!
Download or read book Antiangiogenic Cancer Therapy written by Darren W. Davis and published by CRC Press. This book was released on 2007-07-25 with total page 878 pages. Available in PDF, EPUB and Kindle. Book excerpt: Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev
Download or read book Antiangiogenic Agents in Cancer Therapy written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 2008-01-08 with total page 585 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. Antiangiogenesis is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.
Download or read book Anti Angiogenesis Strategies in Cancer Therapies written by Shaker Mousa and published by Academic Press. This book was released on 2016-11-28 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. - Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents - Reviews FDA-approved anti-angiogenesis agents - Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents - Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Download or read book Tumour Angiogenesis written by R. John Bicknell and published by . This book was released on 1997 with total page 416 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumour Angiogenesis is the first comprehensive book to cover all areas of this rapidly expanding research area. Each chapter is written by world experts in the field and topics covered include in vivo models, mechanisms, inhibition, and the role of macrophages, cytokines, proteases,extracellular matrix components, nitric oxide, prostanoids and oncogenes/tumour suppressor genes in angiogenesis. Other chapters examine the role of specific growth factors in angiogenesis - these include vascular endothelial growth factor, the basic fibroblast growth factor family, transforminggrowth factor-beta, tumour necrosis factor-alpha, platelet-derived endothelial cell growth factor/thymidine phosphorylase and pleiotrophin and related molecules. Clinical issues are addressed in chapters that deal with the prognostic and predictive value of tumour microvessel density and thetherapeutic significance of microregional blood flow. The two final chapters examine the feasibility of targeting tumour vasculature using either antibodies or gene therapy.
Download or read book Tumor Vascularization written by Domenico Ribatti and published by Academic Press. This book was released on 2020-01-21 with total page 198 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor Vascularization discusses the different types of growth of tumor blood vessels and their implications on research and healthcare. The book is divided into three parts: the first one, General Mechanisms, discusses different vessel growth mechanisms, such as sprouting angiogenesis, non-angiogenesis dependent growth, intussusceptive microvascular growth, vascular co-option and vasculogenic mimicry. The second and third parts, entitled Clinical Implications and Therapeutic Implications are dedicated to translating recent findings in this field to patient treatment and healthcare. This book is a valuable source for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in tumor progression and blood vessels. Explains new, non-orthodox concepts recently developed and related to the modality of growth of tumor blood vessels Provides information on the types of angiogenesis, non-angiogenesis dependent growth and vascular co-option, discussing both their similarities and differences Encompasses a discussion on clinical implications of tumor vascularization to translate research findings into treatment
Download or read book Tumor Angiogenesis Regulators written by Ruben R. Gonzalez-Perez and published by CRC Press. This book was released on 2013-05-09 with total page 464 pages. Available in PDF, EPUB and Kindle. Book excerpt: The emphasis of this book is on mechanisms and pathways regulating the expression and actions of classical and novel tumor angiogenesis regulators. The contributors discuss their underlying biology as well as anti-angiogenic drugs currently in use to fight different cancers. The book provides an insight on how factors such as obesity, diabetes, and other metabolic disorders can influence the development and growth of cancer. It is of significant interest not only to oncologists but also to a wide range of medical practitioners and researchers.
Download or read book Tumor Angiogenesis written by Sophia Ran and published by BoD – Books on Demand. This book was released on 2012-02-17 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor angiogenesis is the main process responsible for the formation of new blood vessels that promote tumor growth and metastasis. This process is driven by potent pro-angiogenic factors that are predominant in the tumor environment and are produced by both malignant cells and the host cells recruited to the tumor site. Tumor environment is characterized by the imbalance between pro-angiogenic and anti-angiogenic factors, which drives the construction of numerous but structurally defective vessels. These poorly perfused and abnormal vessels significantly contribute to the tumor pathology not only by supporting the expansion of the tumor mass but also by promoting chronic inflammation, enhancing thrombosis, impeding drug delivery, and disseminating tumor cells. These problems associated with tumor vasculature continue to attract great attention of scientists and clinicians interested in advancing the understanding of tumor biology and development of new drugs. This book complies a series of reviews that cover a broad spectrum of current topics related to the pathology of tumor blood vessels including mechanisms inducing new vessels, identification of new targets for inhibition of tumor angiogenesis, and potential clinical use of known and novel anti-angiogenic therapies. The book provides an update on tumor angiogenesis that could be useful for oncologists, cancer researchers and biologists with interests in vascular and endothelial cell behavior in the context of cancer.
Download or read book Biochemical Basis and Therapeutic Implications of Angiogenesis written by Jawahar L. Mehta and published by Springer. This book was released on 2017-08-28 with total page 542 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book covers the latest developments in the therapeutic implications of angiogenesis, ranging from angiogenesis in the brain, angiogenesis in cancer, angiogenesis’ role in atherosclerosis and heart disease as well as metabolic disorders and peripheral vascular disease. The book is comprehensive in its coverage of angiogenesis in a diverse set of diseases and examines the role of cellular and subcellular structures during the development of angiogenesis. Well-organized and thorough, this is an ideal book for researchers and biomedical engineers working in the field of therapeutic implications of angiogenesis. This book also: Covers the basics of the physiology of angiogenesis, including VEGF pathways in angiogenesis, integr ins in angiogenesis, angiogenesis and exercise physiology, and more Details the role of angiogenesis in atherosclerosis and heart disease, including vascular endothelial growth factor and atherosclerotic plaque progression as well as angiogenesis and heart failure Illustrates in detail brain angiogenesis after stroke and the relationship between angiogenesis and Alzheimer's disease
Download or read book History of Research on Tumor Angiogenesis written by Domenico Ribatti and published by Springer Science & Business Media. This book was released on 2008-12-16 with total page 126 pages. Available in PDF, EPUB and Kindle. Book excerpt: In 1971, J. Folkman published in the “New England Journal of Medicine” a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980’s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors.
Download or read book Tumor Angiogenesis written by Dieter Marmé and published by Springer. This book was released on 2019-10-18 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.
Download or read book Anti Angiogenesis Drug Discovery and Development Volume 5 written by Atta-ur-Rahman and published by Bentham Science Publishers. This book was released on 2020-10-05 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, and wound healing disorders. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. The fifth volume brings together reviews on the following topics: - Targeted therapy for tumor vasculature - Anti-angiogenic therapy for breast and prostate cancers (including information updates on clinical trials) - Microbe-based and other novel antiangiogenesis therapies such as chromene-based agents
Download or read book Physiologic and Pathologic Angiogenesis written by Dan Simionescu and published by BoD – Books on Demand. This book was released on 2017-04-05 with total page 466 pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of this book is to highlight novel advances in the field and to incentivize scientists from a variety of fields to pursue angiogenesis as a research avenue. Blood vessel formation and maturation to capillaries, arteries, or veins is a fascinating area which can appeal to multiple scientists, students, and professors alike. Angiogenesis is relevant to medicine, engineering, pharmacology, and pathology and to the many patients suffering from blood vessel diseases and cancer, among others. We are hoping that this book will become a source of inspiration and novel ideas for all.
Download or read book Vascular Disruptive Agents for the Treatment of Cancer written by Tim Meyer and published by Springer Science & Business Media. This book was released on 2010-09-02 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).
